Abstract: The object of the present invention is to provide a pharmaceutical agent which activate mitochondrial function, particularly, an inexpensive pharmaceutical agent. The problem can be solved by a mitochondrial function activator of the present invention, comprising ?-alanine or glycine, or a salt thereof.

Abstract: Provided is a composition for a gas seal member that can form a gas seal member for a high-pressure hydrogen device that is capable of sufficiently inhibiting both swelling destruction and blister destruction. The composition for a gas seal member is a composition for a gas seal member used in a high-pressure hydrogen environment and contains an elastomer and fibrous carbon nanostructures. The fibrous carbon nanostructures are contained in a proportion of not less than 1 part by mass and not more than 10 parts by mass per 100 parts by mass of the elastomer. An area fraction S (%) of aggregates of the fibrous carbon nanostructures in a cross-section of the composition for a gas seal member and a volume percentage V (volume %) of the fibrous carbon nanostructures in the composition for a gas seal member satisfy a relationship 0?S/V?2.0.

Abstract: A PPR protein with high performance is provided. A PPR protein that binds to a long nucleotide sequence is provided by linking motifs in a number larger than conventionally used 7 to 14. A PPR motif is provided, of which typical examples are the followings: (A-1) a PPR motif consisting of the sequence of SEQ ID NO: 9 or 401, (C-1) a PPR motif consisting of the sequence of SEQ ID NO: 10, (G-1) a PPR motif consisting of the sequence of SEQ ID NO: 11, and (U-1) a PPR motif consisting of the sequence of SEQ ID NO: 12. These motifs are useful as PPR motifs for adenine, cytosine, guanine, and uracil in a target nucleotide sequence, respectively.

Abstract: The present invention provides a pharmaceutical for preventing and/or treating non-ischemic cardiomyopathy, the pharmaceutical comprising dendritic cells obtained by a method comprising a step of culturing mononuclear cells in the presence of GM-CSF and IL-2 and a step of pulsing the cultured cells with ?-galactosylceramide.

Abstract: A method is provided for integrating a DNA fragment of a desired base sequence into a site located adjacent to a binding region of a DNA-binding protein bound to a DNA molecule, the method including bringing the DNA fragment having a base sequence including a transposase-binding sequence and the desired base sequence close to the binding region using a specific binding substance to the DNA-binding protein, binding transposase to the transposase-binding sequence, and activating the transposase such that the DNA fragment of the desired base sequence is integrated into the site located adjacent to the binding region.

Abstract: To provide a heat generating material in which a decrease in hydrogen absorption performance and amount of heat generation can be suppressed at the time of use at a high temperature, and physical properties such as hydrogen absorption performance and amount of heat generation are further improved. The heat generating material includes: a first metal having a melting point of 230° C. or more; and a second metal having a melting point higher than the melting point of the first metal, in which, at this time, at least one of the first metal or the second metal has a hydrogen solubility greater than silver at a temperature less than the melting point of the second metal, a hydride of at least one of the first metal or the second metal has a standard enthalpy of formation equal to or more than a standard enthalpy of formation of CaH2, and heat is generated when the first metal and the second metal come into contact with hydrogen gas at a temperature less than the melting point of the second metal.

Abstract: Provided are compounds represented by, for example, formula (1) (wherein R1, R2, R3 and R4 each independently represent a hydrogen atom, an alkyl group, or a heteroaryl group, not all of R1, R2, R3 and R4 being hydrogen atoms), a luminescent material including at least one compound selected from among the compounds, and a luminescent element including the luminescent material.

Abstract: Provided is an organic modulation element including an organic modulation layer containing a plurality of organic semiconductor molecules, a first electrode, and a second electrode. Each of the plurality of organic semiconductor molecules is a molecule in which an excited state enabling reverse intersystem crossing from a lowest excited triplet state to a lowest excited singlet state is formed due to irradiation with the input light. In each of the plurality of organic semiconductor molecules, an intersystem crossing rate constant from the lowest excited singlet state to the lowest excited triplet state is greater than a reverse intersystem crossing rate constant from the lowest excited triplet state to the lowest excited singlet state, and the reverse intersystem crossing rate constant from the lowest excited triplet state to the lowest excited singlet state is greater than a non-radiative deactivation rate constant from the lowest excited triplet state to a ground state.

Abstract: An immunoregulatory agent containing a regulatory agent that regulates Dedicator of cytokinesis 2 (DOCK2)-mediated Rac activation as an active ingredient is provided.

Abstract: In order to improve aggregation property of a PPR protein, the A6 amino acid of the 1st PPR motif from the N-terminus (M1) is made more hydrophilic. Further, the A9 amino acid of M1 is made to be a hydrophilic amino acid or glycine. The A6 amino acid is preferably asparagine or aspartic acid, and the A9 amino acid is preferably glutamine, glutamic acid, lysine, or glycine. Proteins containing such a PPR motif as M1 motif may have not only improved aggregation property, but also high binding power to a target nucleic acid.

Abstract: To provide an aqueous sodium ion secondary battery which can achieve a high electrochemical capacity as compared with a known sodium ion secondary battery having an aqueous electrolytic solution. An aqueous sodium ion secondary battery includes a cathode, an anode, an electrolytic solution and a separator, wherein the cathode has at least a cathode active material containing at least a sodium transition metal polyanion represented by the formula Na3-xMPO4CO3 (M is at least one member selected from the group consisting of Fe, Mn, Ni and Co, and x is 0 or more and 2 or less), and the electrolytic solution is an aqueous electrolytic solution.

Abstract: An object of the present invention is to provide a means for fixing a pancreatic resection stump created during an operation for resecting a portion of the pancreas. The present invention provides a polymeric surgical clip characterized in that the clip comprises a first arm portion, a second arm portion, and a resilient hinge portion joining the first and second arm portions together, both the arm portions are joined to the resilient hinge portion at their bases, the first arm portion has a convex outer surface and a concave inner surface clamping the pancreas, the second arm portion has a convex or flat outer surface and a concave or flat inner surface clamping the pancreas, the first arm portion forms at its distal end a deflectable hook portion curved toward the second arm portion, and the clip is configured so that, in a closed position, a distal end of the second arm portion enters inside the curved hook portion and engages with the hook portion to lock the clip in the closed position.

Abstract: A DPP-IV inhibitor and a food with functional claims, which comprises methylated catechin as a novel active ingredient, are provided.

Abstract: Provided is a catalyst that has excellent oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) catalytic activity and is useful as a catalyst for water electrolysis, an electrode catalyst for an air battery, or the like. The catalyst includes (A) either or both of Ni atoms and Fe atoms, (B) thiourea, and (C) fibrous carbon nanostructures. It is preferable that the catalyst includes (A) Ni atoms and Fe atoms, that the thiourea is coordinated with the Ni atoms and the Fe atoms, and that a mass ratio of the content of a Ni-thiourea coordination compound relative to the content of an Fe-thiourea coordination compound (Ni-thiourea coordination compound/Fe-thiourea coordination compound) is not less than 5/95 and not more than 70/30.

Abstract: A light emitting device of an embodiment includes a first electrode, a second electrode facing the first electrode, and multiple organic layers disposed between the first electrode and the second electrode. At least one among the organic layers includes a fused polycyclic compound represented by Formula 1 below, thereby showing improved emission efficiency.

Abstract: Provided is a low-cost catalyst that has excellent oxygen reduction reaction (ORR) catalytic activity and is useful as a catalyst for water electrolysis, an electrode catalyst for an air battery, or the like. The catalyst includes (A) Ni atoms, (B) a condensate of thiourea and formaldehyde, and (C) porous carbon.

Abstract: A modality for preventing or treating fibrotic diseases by identifying a marker protein for myofibroblasts is provided. The present invention relates to prophylactic or therapeutic agents for fibrotic diseases, which contain an inhibitor of GPR176 as an active ingredient.

Abstract: Disclosed is an organic light-emitting device using a compound capable of emitting delayed fluorescence and capable of undergoing intramolecular hydron transfer. The compound includes, for example, a compound represented by the general formula. X1 to X3 each represent O or S; R1 to R6 each represent nH or a substituent; n, n1 to n3 each represent an integer of 1 to 3.

Abstract: An optical measuring device for measuring light emitted from a sample includes a container cavity for receiving a container in which the sample is enclosed; a light detection unit for detecting light from the sample; a light guide path for guiding the light from the sample to the light detection unit; and a light absorbing unit for absorbing incident light. An end of the light guide path to receive the incident light faces the container cavity, a light exit end of the light guide path faces the light detection unit, and the light absorbing unit covers the perimeter of the light guide path other than the light-receiving-end and the light exit end thereof.

Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below wherein R5 in the group represented by Formula (3) is hydrogen.